Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells $126,742.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $56.33, for a total value of $126,742.50. Following the transaction, the chief operating officer owned 156,760 shares of the company’s stock, valued at approximately $8,830,290.80. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total value of $111,420.00.
• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total transaction of $127,867.50.

Vaxcyte Price Performance

PCVX opened at $58.71 on Thursday. The firm has a fifty day moving average price of $52.14 and a 200 day moving average price of $53.80. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The stock has a market cap of $8.48 billion, a P/E ratio of -8.53 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the prior year, the business posted ($1.04) EPS. Equities analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors have recently bought and sold shares of PCVX. Janus Henderson Group PLC boosted its stake in shares of Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after acquiring an additional 3,188,687 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Vaxcyte by 35.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Vaxcyte by 18.5% in the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after purchasing an additional 933,539 shares in the last quarter. State Street Corp lifted its holdings in Vaxcyte by 4.1% in the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after purchasing an additional 194,116 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP boosted its stake in Vaxcyte by 7.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock worth $187,698,000 after purchasing an additional 283,265 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on PCVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Monday. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and an average price target of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.